YORK PHARMA (AIM:YRK) TO ANNOUNCE PRELIMINARY RESULTS 2006 ON FRIDAY 24th NOVEMBER

For the year ended 30th September 2006
Friday 24th November 2006

Hitchin, UK, November 15th 2006 – York Pharma plc, the AIM-listed (AIM: YRK) strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology, will announce its preliminary results for the year ended 30th September 2006 on Friday 24th November 2006.

— ENDS —

About York Pharma plc

York Pharma is an AIM-listed strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology. Its portfolio now targets skin diseases that make up approximately 75% of the global $10.4bn dermatology market. The Company's lead product Abasol, an entirely new drug for the treatment of fungal infections of the skin, is anticipated to be commercialised from H1 07. For further information, please go to www.yorkpharma.com .

For more information, please contact:

Northbank Communications
Tel: +44 (0) 203 008 7550
Annabel Entress
yorkpharma@northbankcommunications.com